Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial
Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2923-2936
DOI: 10.1016/j.jtha.2026.04.028 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Danielle Carole Roy und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: droy058@uottawa.ca. Hauptthemen laut MEDLINE: Antineoplastic Agents, Decision Support Techniques, Factor Xa Inhibitors, Hemorrhage. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, LEO Pharma Research Foundation, Pfizer.
Themen: Thromboseprophylaxe, Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Patients with cancer are at elevated risk of venous thromboembolism (VTE). While primary thromboprophylaxis reduces VTE incidence, it also increases bleeding risk, necessitating accurate risk stratification. Existing tools (eg, the Khorana score) have modest predictive value, and bleeding risk models have not been validated in ambulatory patients with cancer. OBJECTIVES: To develop and internally validate prediction models for VTE and clinically relevant bleeding in ambulatory patients with cancer initiating chemotherapy. METHODS: We used data from 514 participants in the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients randomized trial. Outcomes included objectively confirmed VTE and clinically relevant bleeding over 7 months. For each outcome, we trained 3 models: logistic regression with L1 regularization and 2 extreme gradient boosting models (1 using all variables, including biomarkers and genetic data; 1 using only routinely collected variables). Performance was evaluated using optimism-adjusted area under the curve (AUC) values, precision-recall AUC values, calibration, and diagnostic statistics. RESULTS: VTE and clinically relevant bleeding occurred in 8.4% and 9.0% of patients, respectively. The full-variable extreme gradient boosting model performed best (VTE AUC: 0.92; bleeding AUC: 0.90). Key VTE predictors included factor V Leiden, topoisomerase inhibitor use, apixaban, stomach or pancreatic cancer, hemoglobin and high-sensitivity troponin T whereas top bleeding predictors included extracellular vesicles procoagulant activity, N-terminal pro-B-type natriuretic peptide, C-reactive protein, age, body mass index, and blood counts. CONCLUSION: In this proof-of-concept study, prediction models incorporating biomarker and genetic variables accurately predicted VTE and clinically relevant bleeding in patients with cancer, though caution is warranted due to the modest sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: droy058@uottawa.ca.
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute…
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Förderung
- Sanofi
- LEO Pharma Research Foundation
- Pfizer
Zitieren
APA
Roy, D. C., Wang, T. F., Wells, P., Mallick, R., Burger, D., Carrier, M., & Hawken, S. (2026). Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial. Journal of Thrombosis and Haemostasis, 24(8), 2923-2936. https://doi.org/10.1016/j.jtha.2026.04.028
Vancouver
Roy DC, Wang TF, Wells P, Mallick R, Burger D, Carrier M, et al. Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial. Journal of Thrombosis and Haemostasis. 2026;24(8):2923-2936. doi:10.1016/j.jtha.2026.04.028
BibTeX
@article{Roy2026,
author = {Roy, Danielle Carole and Wang, Tzu-Fei and Wells, Philip and Mallick, Ranjeeta and Burger, Dylan and Carrier, Marc and Hawken, Steven},
title = {Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {8},
pages = {2923--2936},
doi = {10.1016/j.jtha.2026.04.028}
}
EUVIMED